vs

Side-by-side financial comparison of PLAYSTUDIOS, Inc. (MYPS) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

RIGEL PHARMACEUTICALS INC is the larger business by last-quarter revenue ($69.8M vs $55.4M, roughly 1.3× PLAYSTUDIOS, Inc.). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs -24.7%, a 408.8% gap on every dollar of revenue. On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs -18.3%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs -15.6%).

PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

MYPS vs RIGL — Head-to-Head

Bigger by revenue
RIGL
RIGL
1.3× larger
RIGL
$69.8M
$55.4M
MYPS
Growing faster (revenue YoY)
RIGL
RIGL
+39.5% gap
RIGL
21.2%
-18.3%
MYPS
Higher net margin
RIGL
RIGL
408.8% more per $
RIGL
384.0%
-24.7%
MYPS
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
-15.6%
MYPS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MYPS
MYPS
RIGL
RIGL
Revenue
$55.4M
$69.8M
Net Profit
$-13.7M
$268.1M
Gross Margin
91.5%
Operating Margin
-17.7%
33.2%
Net Margin
-24.7%
384.0%
Revenue YoY
-18.3%
21.2%
Net Profit YoY
38.9%
1769.2%
EPS (diluted)
$-0.12
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MYPS
MYPS
RIGL
RIGL
Q4 25
$55.4M
$69.8M
Q3 25
$57.6M
$69.5M
Q2 25
$59.3M
$101.7M
Q1 25
$62.7M
$53.3M
Q4 24
$67.8M
$57.6M
Q3 24
$71.2M
$55.3M
Q2 24
$72.6M
$36.8M
Q1 24
$77.8M
$29.5M
Net Profit
MYPS
MYPS
RIGL
RIGL
Q4 25
$-13.7M
$268.1M
Q3 25
$-9.1M
$27.9M
Q2 25
$-2.9M
$59.6M
Q1 25
$-2.9M
$11.4M
Q4 24
$-22.4M
$14.3M
Q3 24
$-3.1M
$12.4M
Q2 24
$-2.6M
$-1.0M
Q1 24
$-567.0K
$-8.2M
Gross Margin
MYPS
MYPS
RIGL
RIGL
Q4 25
91.5%
Q3 25
93.2%
Q2 25
95.6%
Q1 25
91.7%
Q4 24
89.9%
Q3 24
85.5%
Q2 24
92.4%
Q1 24
93.1%
Operating Margin
MYPS
MYPS
RIGL
RIGL
Q4 25
-17.7%
33.2%
Q3 25
-13.6%
40.9%
Q2 25
-5.9%
60.1%
Q1 25
-4.4%
23.9%
Q4 24
-33.1%
28.9%
Q3 24
-6.7%
25.4%
Q2 24
-5.5%
1.2%
Q1 24
-2.2%
-23.6%
Net Margin
MYPS
MYPS
RIGL
RIGL
Q4 25
-24.7%
384.0%
Q3 25
-15.8%
40.2%
Q2 25
-5.0%
58.6%
Q1 25
-4.6%
21.5%
Q4 24
-33.1%
24.9%
Q3 24
-4.3%
22.5%
Q2 24
-3.6%
-2.8%
Q1 24
-0.7%
-27.9%
EPS (diluted)
MYPS
MYPS
RIGL
RIGL
Q4 25
$-0.12
$14.11
Q3 25
$-0.07
$1.46
Q2 25
$-0.02
$3.28
Q1 25
$-0.02
$0.63
Q4 24
$-0.18
$0.82
Q3 24
$-0.02
$0.70
Q2 24
$-0.02
$-0.06
Q1 24
$0.00
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MYPS
MYPS
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$104.9M
$155.0M
Total DebtLower is stronger
$52.5M
Stockholders' EquityBook value
$227.9M
$391.5M
Total Assets
$290.6M
$513.6M
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MYPS
MYPS
RIGL
RIGL
Q4 25
$104.9M
$155.0M
Q3 25
$106.3M
$137.1M
Q2 25
$112.9M
$108.4M
Q1 25
$107.1M
$77.1M
Q4 24
$109.2M
$77.3M
Q3 24
$105.2M
$61.1M
Q2 24
$106.3M
$49.1M
Q1 24
$127.0M
$49.5M
Total Debt
MYPS
MYPS
RIGL
RIGL
Q4 25
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Q1 24
$60.0M
Stockholders' Equity
MYPS
MYPS
RIGL
RIGL
Q4 25
$227.9M
$391.5M
Q3 25
$238.9M
$117.6M
Q2 25
$245.3M
$81.9M
Q1 25
$244.1M
$18.6M
Q4 24
$244.7M
$3.3M
Q3 24
$265.2M
$-14.6M
Q2 24
$263.6M
$-29.9M
Q1 24
$288.4M
$-31.7M
Total Assets
MYPS
MYPS
RIGL
RIGL
Q4 25
$290.6M
$513.6M
Q3 25
$299.2M
$242.5M
Q2 25
$316.2M
$206.7M
Q1 25
$313.8M
$176.0M
Q4 24
$323.0M
$164.0M
Q3 24
$330.6M
$139.4M
Q2 24
$333.4M
$128.4M
Q1 24
$357.5M
$126.5M
Debt / Equity
MYPS
MYPS
RIGL
RIGL
Q4 25
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
18.25×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MYPS
MYPS
RIGL
RIGL
Operating Cash FlowLast quarter
$3.7M
$22.0M
Free Cash FlowOCF − Capex
$3.6M
FCF MarginFCF / Revenue
6.5%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters
$25.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MYPS
MYPS
RIGL
RIGL
Q4 25
$3.7M
$22.0M
Q3 25
$5.7M
$24.0M
Q2 25
$13.6M
$30.5M
Q1 25
$3.3M
$-893.0K
Q4 24
$11.6M
$14.5M
Q3 24
$14.6M
$21.7M
Q2 24
$14.5M
$302.0K
Q1 24
$5.0M
$-5.0M
Free Cash Flow
MYPS
MYPS
RIGL
RIGL
Q4 25
$3.6M
Q3 25
$5.4M
Q2 25
$13.2M
Q1 25
$3.2M
Q4 24
$11.5M
Q3 24
$13.9M
Q2 24
$12.8M
Q1 24
$3.6M
FCF Margin
MYPS
MYPS
RIGL
RIGL
Q4 25
6.5%
Q3 25
9.3%
Q2 25
22.3%
Q1 25
5.1%
Q4 24
16.9%
Q3 24
19.6%
Q2 24
17.6%
Q1 24
4.6%
Capex Intensity
MYPS
MYPS
RIGL
RIGL
Q4 25
0.2%
Q3 25
0.5%
Q2 25
0.7%
Q1 25
0.2%
Q4 24
0.2%
Q3 24
0.9%
Q2 24
2.4%
Q1 24
1.9%
Cash Conversion
MYPS
MYPS
RIGL
RIGL
Q4 25
0.08×
Q3 25
0.86×
Q2 25
0.51×
Q1 25
-0.08×
Q4 24
1.01×
Q3 24
1.75×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons